EGFR Activation and Conformational "Convergence": An Emerging Allosteric Model From Cancer Mutations

Area of Science:

• Molecular Biology
• Oncology
• Structural Biology

Background:

• The Epidermal Growth Factor Receptor (EGFR) is a key oncogene, but its activation mechanism remains incompletely understood due to limited full-length structural data and inherent flexibility.
• EGFR mutations exhibit tissue-specific patterns and influence drug sensitivity, particularly in lung cancer and glioblastoma (GBM).
• Lung cancer mutations primarily affect the kinase domain, while GBM mutations often target the ectodomain (ECD), yet share drug response profiles.

Purpose of the Study:

• To elucidate the coupling mechanism between the extracellular and intracellular domains of EGFR, focusing on an intermediate ectodomain transition state observed in GBM.
• To explain the shared drug responses in GBM by analyzing the structural impact of ectodomain mutations.

Main Methods:

• Recapitulation of existing structural and mutational data for EGFR.
• Analysis of antibody detection and molecular simulations to characterize an intermediate ECD state.
• Comparison of GBM and lung cancer mutation profiles and their impact on receptor activation.

Main Results:

• An intermediate ECD transition state, involving flexible rotation of a key fragment, is identified and linked to GBM mutations, including the common EGFRvIII deletion.
• Convergent missense and deletion mutations in the ECD of GBM target the same flexible region, suggesting a common mechanism.
• A cryptic epitope is associated with this intermediate state, offering a molecular basis for shared drug responses in GBM.

Conclusions:

• EGFR activation is regulated by an allosteric mechanism where extracellular and intracellular domains are coupled in preformed dimers, with ECD rigidity preventing kinase activation.
• GBM mutations bypass this steric blockade by flexibilizing the ECD, while lung cancer mutations directly enhance kinase activity, leading to distinct drug sensitivities.
• Understanding the EGFR ectodomain's role in GBM pathogenesis and drug response is crucial for developing targeted therapies.